Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
Audrey M Sigmund,* Kieran D Sahasrabudhe,* Bhavana Bhatnagar Division of Hematology, Department of Internal Medicine, The Ohio State University and the Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA*These authors contributed equally to this workCorrespondence: Bhavana Bha...
Enregistré dans:
Auteurs principaux: | Sigmund AM, Sahasrabudhe KD, Bhatnagar B |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b11495eba1d74f478741d26b3469e17b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
par: Bhutani D, et autres
Publié: (2017) -
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
par: Megías-Vericat JE, et autres
Publié: (2019) -
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
par: Karantanos T, et autres
Publié: (2017) -
Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
par: Hagop M. Kantarjian, et autres
Publié: (2021) -
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
par: Gupta VA, et autres
Publié: (2013)